TickerStat.comEloxx Pharmaceuticals annual operating expenses
2010
2012
2013
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eloxx Pharmaceuticals Operating Expenses Growth & History (ELOX)
Eloxx Pharmaceuticals's operating expenses was $6.4M for fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.4M | −$2.4M | −27.06% |
| 2024 | 2024-12-31 | $8.8M | −$8.5M | −48.94% |
| 2023 | 2023-12-31 | $17.3M | −$17.1M | −49.77% |
| 2022 | 2022-12-31 | $34.4M | −$31.6M | −47.86% |
| 2021 | 2021-12-31 | $66.0M | $32.6M | +97.33% |
| 2020 | 2020-12-31 | $33.5M | −$17.1M | −33.82% |
| 2019 | 2019-12-31 | $50.6M | $3.0M | +6.29% |
| 2018 | 2018-12-31 | $47.6M | $27.2M | +133.28% |
| 2017 · Dec 31 | 2017-12-31 | $20.4M | $10.6M | +107.22% |
| 2016 · Dec 31 | 2016-12-31 | $9.8M | $3.6M | +56.59% |
| 2015 · Dec 31 | 2015-12-31 | $6.3M | — | — |
| 2013 | 2013-06-30 | $4.7M | −$961,028 | −17.13% |
| 2012 | 2012-06-30 | $5.6M | — | — |
| 2010 | 2010-06-30 | $5.0M | — | — |
Eloxx Pharmaceuticals quarterly operating expenses
Q2.12
Q3.12
Q2.13
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.5M | $2.9M | +181.29% |
| Q1 2026 | 2026-03-31 | $3.8M | $2.6M | +210.56% |
| Q2 2025 | 2025-06-30 | $1.6M | — | — |
| Q1 2025 | 2025-03-31 | $1.2M | — | — |
| Q4 2023 | 2023-12-31 | $4.0M | −$2.0M | −33.18% |
| Q3 2023 | 2023-09-30 | $3.6M | −$3.5M | −49.08% |
| Q2 2023 | 2023-06-30 | $4.1M | −$6.2M | −59.79% |
| Q1 2023 | 2023-03-31 | $5.5M | −$5.5M | −49.94% |
| Q4 2022 | 2022-12-31 | $6.0M | −$5.6M | −48.17% |
| Q3 2022 | 2022-09-30 | $7.1M | −$3.1M | −30.29% |
| Q2 2022 | 2022-06-30 | $10.3M | −$25.4M | −71.18% |
| Q1 2022 | 2022-03-31 | $11.0M | $2.5M | +30.18% |
| Q4 2021 | 2021-12-31 | $11.6M | $5.8M | +100.31% |
| Q3 2021 | 2021-09-30 | $10.2M | $3.9M | +62.72% |
| Q2 2021 | 2021-06-30 | $35.7M | $28.1M | +370.99% |
| Q1 2021 | 2021-03-31 | $8.4M | −$5.4M | −38.88% |
| Q4 2020 | 2020-12-31 | $5.8M | −$5.7M | −49.46% |
| Q3 2020 | 2020-09-30 | $6.3M | −$6.5M | −50.73% |
| Q2 2020 | 2020-06-30 | $7.6M | −$6.7M | −46.99% |
| Q1 2020 | 2020-03-31 | $13.8M | $1.8M | +14.95% |
| Q4 2019 | 2019-12-31 | $11.5M | −$2.6M | −18.61% |
| Q3 2019 | 2019-09-30 | $12.8M | $1.4M | +12.49% |
| Q2 2019 | 2019-06-30 | $14.3M | $768,000 | +5.67% |
| Q1 2019 | 2019-03-31 | $12.0M | $3.4M | +40.11% |
| Q4 2018 | 2018-12-31 | $14.1M | $3.5M | +33.42% |
| Q3 2018 | 2018-09-30 | $11.4M | $7.4M | +184.00% |
| Q2 2018 | 2018-06-30 | $13.5M | $10.4M | +326.01% |
| Q1 2018 · Mar 31 | 2018-03-31 | $8.5M | $5.9M | +224.77% |
| Q4 2017 | 2017-12-31 | $10.6M | — | — |
| Q1 2018 · Sep 30 | 2017-09-30 | $4.0M | — | — |
| Q4 2017 | 2017-06-30 | $3.2M | — | — |
| Q1 2017 · Mar 31 | 2017-03-31 | $2.6M | — | — |
| Q2 2013 | 2012-12-31 | $1.3M | −$356,091 | −21.50% |
| Q3 2012 | 2012-03-31 | $1.1M | — | — |
| Q2 2012 | 2011-12-31 | $1.7M | — | — |
Eloxx Pharmaceuticals operating expenses trends
Over the last five fiscal years, Eloxx Pharmaceuticals's operating expenses decreased from $33.5M to $6.4M, a change of −$27.0M. The latest reported quarter, Q2 2026, shows $4.5M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...